Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
A recently proposed therapeutic approach for lysosomal storage disorders (LSDs) relies upon the ability of transcription factor EB (TFEB) to stimulate autophagy and induce lysosomal exocytosis leading to cellular clearance. This approach is particularly attractive in glycogen storage disease type II [a severe metabolic myopathy, Pompe disease (PD)] as the currently available therapy, replacement of the missing enzyme acid alpha-glucosidase, fails to reverse skeletal muscle pathology. PD, a paradigm for LSDs, is characterized by both lysosomal abnormality and dysfunctional autophagy. Here, we show that TFEB is a viable therapeutic target in PD: overexpression of TFEB in a new muscle cell culture system and in mouse models of the disease reduced glycogen load and lysosomal size, improved autophagosome processing, and alleviated excessive accumulation of autophagic vacuoles. Unexpectedly, the exocytosed vesicles were labelled with lysosomal and autophagosomal membrane markers, suggesting that TFEB induces exocytosis of autophagolysosomes. Furthermore, the effects of TFEB were almost abrogated in the setting of genetically suppressed autophagy, supporting the role of autophagy in TFEB-mediated cellular clearance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“strategies based on the enhancement of cellular waste disposal capacity (i.e., TFEB‐TFE3 gene therapy) hold promise of preclinical benefits in these pathological scenarios (Spampanato et al, 2013; Bajaj et al, 2019).”
From Autophagy in major human diseases (2021) · cites this paper as Spampanato et al, 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.
Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., & Yoshimori, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.21.5720 · Cited by 6,605 · cited 2×
“…abnormality in PD muscle fibres – autophagic accumulation (Raben et al, 2012) – was not reproduced in PD myotubes, as demonstrated by immunostaining and western analysis with LC3 [a highly specific autophagosomal marker (Kabeya et al, 2000)] (shown for western blot in Supporting Information Fig S1C).”
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
TFEB Links Autophagy to Lysosomal Biogenesis
Settembre, C., Di Malta, C., Polito, V. A., Arencibia, M. G., Vetrini, F., Erdin, S., Erdin, S. U., Huynh, T., Medina, D., Colella, P., et al. (2011) · Science · doi:10.1126/science.1204592 · Cited by 3,365 · cited 5×
“Furthermore, since TFEB has been shown to promote lysosomal– autophagosomal fusion (Settembre & Ballabio, 2011; Settembre et al, 2011), this approach, unlike most current efforts, has the potential to prevent or resolve autophagic build-up.”
InfluentialSelf-citationA Gene Network Regulating Lysosomal Biogenesis and Function
Sardiello, M., Palmieri, M., di Ronza, A., Medina, D. L., Valenza, M., Gennarino, V. A., Di Malta, C., Donaudy, F., Embrione, V., Polishchuk, R. S., et al. (2009) · Science · doi:10.1126/science.1174447 · Cited by 2,543 · cited 5×
“Plasmids: plasmid containing the full-length 3xFlag-tagged human TFEB (referred to as Flag-TFEB) was described previously (Sardiello et al, 2009); plasmid containing the full-length rat LAMP1 (mCherry-LAMP1) was obtained from Dr. Kristien Zaal (Light Imaging Section, Office of Science & Technology,…”
InfluentialSelf-citationMammalian autophagy: core molecular machinery and signaling regulation
Yang, Z., & Klionsky, D. J. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.11.014 · Cited by 1,956 · cited 1×
“Defects in autophagy, a major lysosome-dependent degradative system (Yang & Klionsky, 2010)], significantly contribute to the pathophysiology of several lysosomal storage diseases (Cao et al, 2006; Cox & Cachon-Gonzalez, 2012; Fukuda et al, 2006a,b; Liao et al, 2007; Lieberman et al, 2012; Settembre…”
A lysosome‐to‐nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB
Settembre, C., Zoncu, R., Medina, D. L., Vetrini, F., Erdin, S., Erdin, S., Huynh, T., Ferron, M., Karsenty, G., Vellard, M. C., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.32 · Cited by 1,920
Self-citationLysosomes: fusion and function
Luzio, J. P., Pryor, P. R., & Bright, N. A. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2217 · Cited by 1,740 · cited 1×
“Lysosomal function depends on the ability of lysosomal membranes to fuse with other vesicles’ membranes and with the plasma membrane (Luzio et al, 2007).”
Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function
Saftig, P., & Klumperman, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2745 · Cited by 1,648 · cited 1×
“LAMPs are considered to be of key importance for lysosomal movement, maturation of autophago-somes and lysosomal exocytosis (Saftig & Klumperman, 2009).”
Roczniak-Ferguson, A., Petit, C. S., Froehlich, F., Qian, S., Ky, J., Angarola, B., Walther, T. C., & Ferguson, S. M. (2012) · Science Signaling · doi:10.1126/scisignal.2002790 · Cited by 1,366
MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB
Martina, J. A., Chen, Y., Gucek, M., & Puertollano, R. (2012) · Autophagy · doi:10.4161/auto.19653 · Cited by 1,333 · cited 6×
“Next, we attempted to activate endogenous TFEB by pharmacologically targeting mTORC1, which has been shown to negatively regulate TFEB (Martina et al, 2012; RoczniakFerguson et al, 2012; Settembre et al, 2012).”
BackgroundMethodInfluentialSelf-citation
Cited by
Items 301–342 of 342
Literature Review and Case Series
Dasouki, M., Jawdat, O., Almadhoun, O. F., Pasnoor, M., McVey, A., Abuzinadah, A. R., Herbelin, L. L., Barohn, R. J., & Dimachkie, M. M. (2014)
Tan, S. (2017) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/72655
Brígido, R. T. E. S. (2016) · doi:10.14393/ufu.te.2016.73 · Cited by 1
Elucidation of the cell signaling pathways mediating innate immunity and host-pathogen interactions
Nabar, N. R. (2019) · Figshare
An in vitro Model for Lysosomal Storage Diseases Using Aspartylglucosaminuria Patient Cells
Kjellman, M. (2020) · UTUPub (University of Turku)
Pooled shRNA Library Screening to Identify Enhancers of Lysosomal Exocytosis
So, K. S. (2016) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Mechanisms of autophagy control through micrornas under cellular stress
Öztürk, D. G. (2019) · Sabanci University
Circadian Regulation of Autophagy in the Heart Via the mTOR Pathway
Love, M., Rabinovich-Nikitin, I., & Kirshenbaum, L. A. (2021) · Advances in biochemistry in health and disease · doi:10.1007/978-3-030-78799-8_9
Dahms, N. M. (2015) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4939-2543-8_3
Matthews, I., Birmbaum, A., Gromova, A., Coutinho, K., McGraw, M., Patterson, D. C., Banks, M. T., Nobles, A. C., Nguyen, N., Miranda, H. C., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1578234/v1
The Regulatory Role and Research Progress of TFEB in Lysosomal Storage Disease
程, 士. (2023) · Bioprocess · doi:10.12677/bp.2023.131001
Exercise regulates TFEB expression to influence body metabolism
Li, J. (2023) · International Journal of Biology and Life Sciences · doi:10.54097/ijbls.v2i1.5223
“In murine models of lysosomal storage disease, activation of TFEB was able to increase autophagic flux in muscle [15,16,25] but in other studies, TFEB activation did not restore lysosomal homeostasis or autophagy in the presence of defective autophagic lysosome reformation (ALR).”
BackgroundAdaptations of autophagy and lysosomal systems upon membrane damage and pathogenic invasion
Bhattacharya, A. (2023) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.73735
Modulation des sphingolipides comme piste thérapeutique dans la sclérose latérale amyotrophique
Bouscary, A. (2020) · theses.fr (ABES) · doi:10.70675/fcfc6e92z9a40z4c36z995dzb38db6cf8edb
Du, K., Chen, H., Zhao, M., Cheng, S., Luo, Y., Zhang, W., & Li, D. (2024) · eLife · doi:10.7554/elife.103137.1
Guerra, M. V., Castro, J., Moreno, A., Balboa, E., Marugán, J., Alvarez, A. R., & Zanlungo, S. (2025) · Antioxidants · doi:10.3390/antiox14050611 · Cited by 1
“…and Frontotemporal Dementia (FTD) diseases [62–64], and that it has also been shown that TFEB overexpression and/or activation is beneficial [22,61,65,66], inhibiting c-Abl in order to increase TFEB in the nucleus could be a therapeutic option for these neurodegenerative and more frequent…”
Das, A., & Datta, R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.10.687576
EGR1 drives cell proliferation by directly stimulating TFEB transcription in response to starvation
Tufano, G. (2024) · Open Research Online (The Open University) · doi:10.21954/ou.ro.00097940
Rab24:n vuorovaikutus HOPS-kompleksin VPS18:n ja Golgin laitteen GM130:n kanssa
Kotiniitty, R. (2024) · UTUPub (University of Turku)
The role of the MIT/TFE family in melanoma
Dias, D. B. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/s0at-ga54
Glycovecteurs pour le ciblage thérapeutique d'une maladie rare lysosomale : la maladie de Pompe
Silva, A. D. (2017) · theses.fr (ABES) · doi:10.70675/458483cezbec6z4277zb67dz629203c5deba
Arotçarena, M.-L. (2019) · theses.fr (ABES) · doi:10.70675/fc7ae442z6823z43c3z8ebazd4960299833b
Verdera, H. C. (2019) · theses.fr (ABES) · doi:10.70675/3d2d8524z211ez4408zbdfbz56c065f452a1
Lysosomal defects in Duchenne muscular dystrophy : advancing combined therapeutic approaches
Jaber, A. (2024) · theses.fr (ABES) · doi:10.70675/d5d1c272z2c2cz4571zb9ccz8134fc1276c2
Venezia, M., Russo, M., Colomba, P., Zizzo, C., Vinci, M., Marsana, E. M., D’Errico, A., Giacalone, I., Duro, G., & Moschetti, M. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102364
“Concurrently, an escalation in the phosphorylation levels of the principal effectors down-stream of AMPK, including TSC2 S1387 and ACC S79 (acetyl-CoA carboxylase), was observed, thereby substantiating the functional activation of this kinase within the pathological scenario [19].”
Lysosomal function and homeostasis: From cellular adaptation to disease pathogenesis
Minami, S., & Hamasaki, M. (2026) · International review of cytology · doi:10.1016/bs.ircmb.2026.04.002
Zhu, J. F., 潘召南, Wang, S., Zhang, H., Wang, Q., Jiang, Z., Wang, Y., Ding, Z., & Li, D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.16.732532
“Impaired lysosomal function disrupts lipid metabolism, autophagy, and inflammation, leading to insulin resistance and β-cell failure [16].”
Pompe Disease: From a Cardiovascular Lens
Ali, A., Thirumavalavan, D., Catanzaro, J. N., Fishkin, T., Makaryus, A. N., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001432
Zhu, J., 潘召南, Wang, S., Wang, Y., Ding, Z., Wang, Q., & Li, D. (2026) · eLife · doi:10.7554/elife.112056
Zhu, J., 潘召南, Wang, S., Wang, Y., Ding, Z., Wang, Q., & Li, D. (2026) · eLife · doi:10.7554/elife.112056.1
Autophagy-lysosomal pathway in neurodegeneration
McDonough, S. R., Rao, A. K., McAleer, J. M., Babrowicz, B. M., & Sharma, M. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00041-0
“Additionally, stimulating TFEB has been effective in mouse models of some neurodegenerative lysosomal storage disorders [372].”
Deng, L., Li, L., Huang, Z., & Huang, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1958455
“Likewise, evidence that TFEB activation improves clearance in storage-disease models supports degradative capacity, but does not independently demonstrate suppression of a disease-causing EV route (Spampanato et al., 2013; Palmieri et al., 2017).”
Self-citationCRISPRa-mediated activation of Tfeb in a fibril-induced alpha-synuclein aggregation modelPreprint
Arvidsson, E., Börjesson, E. P., Sabarese, E., Quintino, L., & Lundberg, C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.16.757246
Metadata
- Authors
- Spampanato, C., Feeney, E., Li, L., Cardone, M., Lim, J., Annunziata, F., Zare, H., Polishchuk, R., Puertollano, R., Parenti, G., Ballabio, A., & Raben, N.
- Affiliations
- Baylor College of Medicine (US)
- National Institutes of Health (US)
- Telethon Institute Of Genetics And Medicine (IT)
- Federico II University Hospital (IT)
- Corresponding author
- Ballabio, Andrea
- Raben, Nina
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2013-04-18
- Volume
- 5
- Issue
- 5
- Pages
- 691-706
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC3662313
- OpenAlex
- W2113698463
- Cited by
- 341
- References
- 68
- Citations by year
- 2026: 9 · 2025: 20 · 2024: 23 · 2023: 20 · 2022: 24 · 2021: 33 · 2020: 29 · 2019: 37 · 2018: 22 · 2017: 22 · 2016: 35 · 2015: 29 · 2014: 28 · 2013: 10
- FWCI
- 23.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- March of Dimes Foundation
- Beyond Batten Disease Foundation
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS078072)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- FP7 Ideas: European Research Council (250154)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- TFEB, Pompe disease, lysosomal storage disease, autophagy, lysosomal exocytosis, acid alpha-glucosidase deficiency, skeletal muscle, therapeutic target, lysosomal dysfunction
- MeSH terms
- Adenoviridae, alpha-Glucosidases, Animals, Autophagy, Cells, Cultured, Disease Models, Animal, Exocytosis, Genetic Vectors, Glycogen, Glycogen Storage Disease Type II, Lysosomes, Mice, Knockout, Muscle, Skeletal, Mice, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.